Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with ZIPRASIDONE ‒ long‐term data (> 12 months) (low certainty).
1 finding from 1 review
Substance use: improvement ‒ (at least 20% reduction in use, TLFB scale) · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes substance use: improvement ‒ (at least 20% reduction in use, TLFB… compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Subjective well‐being · people with both severe mental illness and substance misuse
1 finding from 1 review
Craving · people with both severe mental illness and substance misuse
1 finding from 1 review
Adherence to antipsychotic medication: discontinued medication · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adherence to antipsychotic medication: discontinued medication compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adverse effects. 1. Movement disorders ‐ any extrapyramidal compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Mental state: 2. Specific‐ Positive symptoms, total score‐ average endpoint scores (SADS‐C‐PD scale, lower = better) · people with both severe mental illness and substance misuse
1 finding from 1 review
Substance use: 1. Reduction of cannabis use‐change data (number of joints smoked/week) · people with both severe mental illness and substance misuse
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Clinically important change in life skills (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy short term (up to 12 weeks) compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Cost‐effectiveness (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with QUETIAPINE (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important change in life skills (long term) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (long term) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found